Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.

MLA

Reck, Martin, et al. “Topotecan and Etoposide as First-Line Therapy for Extensive Disease Small Cell Lung Cancer: A Phase II Trial of a Platinum-Free Regimen.” Lung Cancer (Amsterdam, Netherlands), vol. 48, no. 3, June 2005, pp. 409–13. EBSCOhost, https://doi.org/10.1016/j.lungcan.2004.11.013.

APA

Reck, M., Groth, G., Buchholz, E., Goetz, E., Gatzemeier, U., & Manegold, C. (2005). Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung Cancer (Amsterdam, Netherlands), 48(3), 409–413. https://doi.org/10.1016/j.lungcan.2004.11.013

Chicago

Reck, Martin, Gesine Groth, Erika Buchholz, Elif Goetz, Ulrich Gatzemeier, and Christian Manegold. 2005. “Topotecan and Etoposide as First-Line Therapy for Extensive Disease Small Cell Lung Cancer: A Phase II Trial of a Platinum-Free Regimen.” Lung Cancer (Amsterdam, Netherlands) 48 (3): 409–13. doi:10.1016/j.lungcan.2004.11.013.